Ms Sullivan is VP Operations at the Metrics Champion Consortium (MCC), a non-profit organization dedicated to the development and support of performance metrics within the bio/pharmaceutical industry. She received a BS from Trinity College and a MBA from Dartmouth where she was named a Tuck Scholar.
Ken is the chairman of CISCRP and a Senior Research Fellow, Assistant Professor, at Tufts CSDD. He is a well-known speaker and author, serving on several editorial boards including the Drug Information Journal. Ken holds an MBA from the J.L. Kellogg Graduate School of Management at Northwestern U.
With 14+ years of industry experience, Michelle held DM positions at GlaxoWellcome and AZ. As Director, Product Management, Michelle is responsible for the Clinical Trial Planning and Management Portfolio, focused on solutions that aid optimized protocol design, budgeting and study initiation.
Ms Sullivan is VP Operations at the Metrics Champion Consortium (MCC), a non-profit organization dedicated to the development and support of performance metrics within the bio/pharmaceutical industry. She received a BS from Trinity College and a MBA from Dartmouth where she was named a Tuck Scholar.
Description
This session will examine current costs and issues associated with poorly designed protocols and explore new approaches being developed and utilized by organizations to improve protocol design and reduce the incidence of protocol amendments.
Learning Objectives: Summarize the cost of poorly designed protocols List three types of avoidable protocol amendments Identify tools in development and those that are implemented by organizations to improve protocol design quality, feasibility and reduce the incidence of protocol amendments.